Evommune, Inc. · NYSE:EVMN

Evommune — Corporate Update (November 2026)

20 slides from Evommune's corporate update, Nov 4, 2026

  1. Slide 1: EVO570: Potential Best-in-Class VAV1 Molecular Glue Degrader

    EVO570: Potential Best-in-Class VAV1 Molecular Glue Degrader JAK-like efficacy with improved safety could position VAV1 to compete broadly in established JAK markets and beyond © Evommune, Inc.

  2. Slide 2: Disclaimers

    Disclaimers This presentation has been prepared by Evommune, Inc. (“we”, “us” or “our”) and contains forward-looking statements, including: statements about our expectations regarding EVO570, which include the potential results, design, objectives, initiation, timing and progress of current and futu

  3. Slide 3: Advancing Multiple Programs Toward Clinical Proof-of-Concept

    Advancing Multiple Programs Toward Clinical Proof-of-Concept Program/Target Indication Preclinical Phase 1 Phase 2 Phase 3 EVO301 IL-18BP Atopic Dermatitis Ulcerative Colitis Other Indications1 EVO756 MRGPRX2 Migraine EVO570 VAV1 MGD Rheumatoid Arthritis EVO646 TLR 7/8 Antagonist Autoimmune Diseases

  4. Slide 4: EVO570 Opportunity Executive Summary

    EVO570* Opportunity Executive Summary © Evommune, Inc. Why VAV1 JAK-like potential without the liabilities Genetic data supports key role in inflammation Broad I&I potential across autoimmune indications Emerging target; ideal timing for Evommune Immune-cell restricted; drives T- and B-cell receptor

  5. Slide 5: VAV1 Landscape: EVO570 Potential First-in-Class

    VAV1 Landscape: EVO570 Potential First-in-Class Novartis Part A topline could validate the class as early as Q4 2027–Q1 2028 © Evommune, Inc. Sources: Partner 8-K/press releases (Aug & Sep 2026); ClinicalTrials.gov NCT07737743, NCT07801495; InnoCare press releases (Feb & Mar 2026); BioWorld (Jun 202

  6. Slide 6: Transaction Overview

    Transaction Overview © Evommune, Inc. Non-binding term sheet signed 9/10/26; Company runway into 2H 2029 Deal Structure (Ex-Greater China Rights to EVO570) VAV1 and Initial Development Upfront: $20M cash and $10M in warrants exercisable for Evommune stock, issued at signing Royalties: mid-single to

  7. Slide 7: VAV1 Overview

    VAV1 Overview © Evommune, Inc.

  8. Slide 8: VAV1: An Immune-Cell-Specific Guanine Nucleotide Exchange Factor

    BCR CD19 TCR CD28 VAV1 Rac1 Rac1 GTP GDP GTP VAV1: An Immune-Cell-Specific Guanine Nucleotide Exchange Factor © Evommune, Inc. T-Cells B-Cells In the Context of I&I Diseases Cytotoxic T-cells can lead to tissue destruction Production of pro-inflammatory cytokines, such as IL-4, IL-17, and TNF⍺ Provi

  9. Slide 9: Biology Points to VAV1 as an Inflammation Driver

    Biology Points to VAV1 as an Inflammation Driver © Evommune, Inc. Betzler et al., Front Cell Dev Biol 2022; Turner et al., Nat Rev Immunol 2002; Bachman et al., J Immunol 1999; Fischer et al., Curr Biol 1998; Schmidt et al., Science 2022 VAV1-/- mice are viable and fertile, with loss-of-function T-

  10. Slide 10: Opportunity to Address a Wide Range of Complex Autoimmune Indications

    Opportunity to Address a Wide Range of Complex Autoimmune Indications Through Clinically Validated Pathways © Evommune, Inc. Immunological outcome Approved drugs validating the pathway T-cell activation B-cell activation and antibody production Th17 response Pro-inflammatory cytokine production

  11. Slide 11: VAV1 Biology Overlaps with Approved I&I Drug Mechanisms

    VAV1 Biology Overlaps with Approved I&I Drug Mechanisms Seven drug classes span nine indications; VAV1 has direct evidence in each © Evommune, Inc. VAV1 row: direct evidence only (blank = none); Ph2a/b = trial underway / posted, no efficacy data. Source: Evaluate Pharma. T-cell mediated T/B-cell med

  12. Slide 12: EVO570 Meets or Exceeds MRT-6160 and Standard of Care

    EVO570 Meets or Exceeds MRT-6160 and Standard of Care Across All Tested Disease Models © Evommune, Inc. Multiple Sclerosis (MS) Rheumatoid Arthritis (RA) Inflammatory Bowel Disease (IBD) EVO570 previously known as HC118

  13. Slide 13: VAV1: JAK-Like with a More Selective Profile

    VAV1: JAK-Like with a More Selective Profile © Evommune, Inc. VAV1 JAK1 JAK2 JAK3 TYK2 T-cell depletion B-cell depletion (Rituximab) Expression is limited to immune cells Modulates T-cell function Modulates B-cell function Phenotype of KO mouse N/A N/A Modulates cytokine production Immune cell chemo

  14. Slide 14: EVO570 Evommune's VAV1 MGD

    EVO570 Evommune’s VAV1 MGD © Evommune, Inc.

  15. Slide 15: EVO570 Meets Key Development Candidate Criteria

    EVO570 Meets Key Development Candidate Criteria © Evommune, Inc. Selection Criterion Typical Preclinical DC Expectation EVO570 Result Verdict Novelty / IP Novel composition of matter, FTO De novo scaffold; Patent published, LOE 2045 + PTE ✓ Target potency (DC50 / Dmax) Low-nM DC50, Dmax >80% 0.3 nM

  16. Slide 16: EVO570 vs. MRT-6160: Preclinical Head-to-Head Properties

    EVO570 vs. MRT-6160: Preclinical Head-to-Head Properties Demonstrate Potential Superior Best-in-Class Profile © Evommune, Inc. Property MRT-6160 (Novartis) EVO570 EVO570 Advantage VAV1 DC50 (HiBiT, Jurkat) 7 nM 0.3 nM ~20× more potent Max degradation (Dmax) 97% 99% Deeper knockdown CRBN binding IC50

  17. Slide 17: Development Plan

    Development Plan © Evommune, Inc.

  18. Slide 18: Over Half of RA Patients Are Not in Remission

    Over Half of RA Patients Are Not in Remission, with No New Mechanism in 10+ Years © Evommune, Inc. csDMARD: conventional synthetic DMARD (methotrexate, leflunomide, sulfasalazine); bDMARD: biologic DMARD (TNF, IL-6); tsDMARD: targeted synthetic DMARD (JAK); HCQ: hydroxychloroquine; SSZ: sulfasalazin

  19. Slide 19: Development Strategy Leads with RA

    Development Strategy Leads with RA RA opens a path to 12 VAV1 indications © Evommune, Inc. Why RA first 1 Mechanistic fit RA is driven by T and B cells; VAV1 signals downstream of both receptors 2 Fast proof of concept 12-week placebo-controlled study in MTX-IR patients pairs clinical endpoints with

  20. Slide 20: Proposed China Phase 1 Trial Design

    PART A: SAD Dosing 8 Cohorts: Oral dose of EVO570 or pbo (10 per group, 8:2) Proposed China Phase 1 Trial Design Will support global Phase 2 program to begin 2027 © Evommune, Inc. Cohort A1 (0.1 mg) Cohort A8 Cohort A4 Cohort A3 Cohort A2 Cohort B1 Cohort B3 Cohort B2 PART B: MAD Dosing 4 Cohorts: O

Evommune — Corporate Update (November 2026) on 6ix